These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21933873)

  • 1. Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.
    Slepenkin A; Chu H; Elofsson M; Keyser P; Peterson EM
    J Infect Dis; 2011 Nov; 204(9):1313-20. PubMed ID: 21933873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis.
    Pedersen C; Slepenkin A; Andersson SB; Fagerberg JH; Bergström CA; Peterson EM
    PLoS One; 2014; 9(10):e110918. PubMed ID: 25356686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae.
    Chu H; Slepenkin A; Elofsson M; Keyser P; de la Maza LM; Peterson EM
    Int J Antimicrob Agents; 2010 Aug; 36(2):145-50. PubMed ID: 20605703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal immunization with Chlamydia trachomatis, serovar E, protects from a subsequent vaginal challenge with the homologous serovar.
    Peterson EM; You JZ; Motin V; de la Maza LM
    Vaccine; 1999 Jul; 17(22):2901-7. PubMed ID: 10438062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with an acellular vaccine consisting of the outer membrane complex of Chlamydia trachomatis induces protection against a genital challenge.
    Pal S; Theodor I; Peterson EM; de la Maza LM
    Infect Immun; 1997 Aug; 65(8):3361-9. PubMed ID: 9234798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Examination of Chlamydia trachomatis infection in environments mimicking normal and abnormal vaginal pH.
    Yasin B; Pang M; Wagar EA; Lehrer RI
    Sex Transm Dis; 2002 Sep; 29(9):514-9. PubMed ID: 12218842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-clinical pharmacokinetics and anti-chlamydial activity of salicylidene acylhydrazide inhibitors of bacterial type III secretion.
    Ur-Rehman T; Slepenkin A; Chu H; Blomgren A; Dahlgren MK; Zetterström CE; Peterson EM; Elofsson M; Gylfe A
    J Antibiot (Tokyo); 2012 Aug; 65(8):397-404. PubMed ID: 22669447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of immunoglobulin G isotype on the infectivity of Chlamydia trachomatis in a mouse model of intravaginal infection.
    Peterson EM; Cheng X; Motin VL; de la Maza LM
    Infect Immun; 1997 Jul; 65(7):2693-9. PubMed ID: 9199438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.
    Patton DL; Cosgrove Sweeney YT; McCarthy TD; Hillier SL
    Antimicrob Agents Chemother; 2006 May; 50(5):1696-700. PubMed ID: 16641437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity.
    Engström P; Nguyen BD; Normark J; Nilsson I; Bastidas RJ; Gylfe A; Elofsson M; Fields KA; Valdivia RH; Wolf-Watz H; Bergström S
    J Bacteriol; 2013 Sep; 195(18):4221-30. PubMed ID: 23852872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis.
    Achilles SL; Shete PB; Whaley KJ; Moench TR; Cone RA
    Sex Transm Dis; 2002 Nov; 29(11):655-64. PubMed ID: 12438901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge.
    Pal S; Peterson EM; de la Maza LM
    Infect Immun; 1996 Dec; 64(12):5341-8. PubMed ID: 8945586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibitor of type three secretion suppresses acute and chronic Chlamydia trachomatis infection in a novel urogenital Chlamydia model.
    Koroleva EA; Kobets NV; Zayakin ES; Luyksaar SI; Shabalina LA; Zigangirova NA
    Biomed Res Int; 2015; 2015():484853. PubMed ID: 25695086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection.
    Ramsey KH; Shaba N; Cohoon KP; Ault KA
    Infect Dis Obstet Gynecol; 2003; 11(2):81-7. PubMed ID: 14627213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.
    Su H; Parnell M; Caldwell HD
    Vaccine; 1995 Aug; 13(11):1023-32. PubMed ID: 8525685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of multiple genital tract infections with Chlamydia trachomatis in different strains of female mice.
    Lyons JM; Morré SA; Airo-Brown LP; Peña AS; Ito JI
    J Microbiol Immunol Infect; 2005 Dec; 38(6):383-93. PubMed ID: 16341338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.
    Uusitalo P; Hägglund U; Rhöös E; Scherman Norberg H; Elofsson M; Sundin C
    J Antibiot (Tokyo); 2017 Aug; 70(9):937-943. PubMed ID: 28588224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 0.25% chlorhexidine gluconate gel. A protective topical microbicide.
    Patton DL; Sweeney YT; McKay TL; DeMers SM; Clark AM; Rabe LK; Hillier SL
    Sex Transm Dis; 1998 Sep; 25(8):421-4. PubMed ID: 9773435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.
    Pal S; Luke CJ; Barbour AG; Peterson EM; de la Maza LM
    Vaccine; 2003 Mar; 21(13-14):1455-65. PubMed ID: 12615442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of
    Sharma P; Elofsson M; Roy S
    Virulence; 2020 Dec; 11(1):795-804. PubMed ID: 32507000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.